nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

12.04.2020 | Review – Clinical Oncology

The efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis

verfasst von: Jie Zhang, Qi Song, Liang Cai, Ying Xie, Yue Chen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the efficacy of ¹⁷⁷Lu-DOTA0-Tyr3-octreotate (¹⁷⁷Lu-DOTATATE) radionuclide therapy in patients with inoperable or metastatic neuroendocrine tumours (NETs), (PROSPERO ID CRD42019130755).

Methods

All published clinical studies of NETs treated with ¹⁷⁷Lu-DOTATATE were identified based on systematic searches in the PubMed, EMBASE, Cochrane Library, Web of Science and ClinicalTrials.gov databases up to January 2019. Among these studies, only the reports evaluated with the “Response Evaluation Criteria in Solid Tumours (RECIST)” or “Southwest Oncology Group (SWOG)” criteria or both were included. We analysed the disease response rate (DRR) and disease control rate (DCR) of each group to evaluate the efficacy of ¹⁷⁷Lu-DOTATATE.

Results

Fifteen studies were selected from 715 references. The pooled effect in the RECIST group (13 studies) was 27.58% (95% confidence interval (CI) 21.03–35.27%) for the DRR and 79.14% (95% CI 75.83–82.1%) for the DCR. In the SWOG criteria group (7 studies), the pooled effect was 20.59% (95% CI 10.89–35.51%) for the DRR and 78.28% (95% CI 74.39–81.72%) for the DCR. Therefore, the RECIST and SWOG groups showed similar DRRs and DCRs after¹⁷⁷Lu-DOTATATE treatment, indicating that ¹⁷⁷Lu-DOTATATE treatment has excellent efficacy with a control rate of approximately 78–79%. Moreover, adverse effects of ¹⁷⁷Lu-DOTATATE were minimal, including fatigue, nausea, vomiting and hormonal disorders.

Conclusions

For patients with inoperable or metastatic NETs, ¹⁷⁷Lu-DOTATATE is an effective treatment with minimal side effects.

Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest oncology group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460. https://doi.org/10.1200/jco.2002.03.055 CrossRefPubMed

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G (2011) Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38:2125–2135. https://doi.org/10.1007/s00259-011-1902-1 CrossRefPubMed

Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G (2016) Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 43:839–851. https://doi.org/10.1007/s00259-015-3250-z CrossRefPubMed

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342. https://doi.org/10.1001/jamaoncol.2017.0589 CrossRefPubMedPubMedCentral

Delpassand ES, Samarghandi A, Zamanian S et al (2014) Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43:518–525. https://doi.org/10.1097/mpa.0000000000000113 CrossRefPubMed

del Prete M, Buteau FA, Beauregard JM (2017) Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging 44:1490–1500. https://doi.org/10.1007/s00259-017-3688-2 CrossRefPubMed

del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM (2018) Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 46:728–742. https://doi.org/10.1007/s00259-018-4209-7 CrossRefPubMed

Development Core Team R (2011) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Zreiqat A, Willinek W, Biersack HJ, Sabet A (2014) Outcome of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 41:925–933. https://doi.org/10.1007/s00259-013-2677-3 CrossRefPubMed

Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597. https://doi.org/10.1002/cncr.29099 CrossRefPubMed

Hamiditabar M, Ali M, Roys J, Wolin EM, O'Dorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES (2017) Peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years' assessment. Clin Nucl Med 42:436–443. https://doi.org/10.1097/rlu.0000000000001629 CrossRefPubMedPubMedCentral

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186 CrossRefPubMed

Hodi FS, Hwu WJ, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34:1510–1517. https://doi.org/10.1200/jco.2015.64.0391 CrossRefPubMedPubMedCentral

Kalshetty A, Ramaswamy A, Ostwal V, Basu S (2018) Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Nucl Med Commun 39:1143–1149. https://doi.org/10.1097/mnm.0000000000000926 CrossRefPubMed

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39:S103–S112. https://doi.org/10.1007/s00259-011-2039-y CrossRefPubMed

Kim SJ, Pak K, Koo PJ, Kwak JJ, Chang S (2015) The efficacy of ¹⁷⁷Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging 42:1964–1970. https://doi.org/10.1007/s00259-015-3155-x CrossRefPubMed

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefPubMed

Mujica-Mota R, Varley-Campbell J, Tikhonova I et al (2018) Everolimus, lutetium-¹⁷⁷ DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technol Assess 22:1–326. https://doi.org/10.3310/hta22490 CrossRefPubMedPubMedCentral

Oberg K, Jelic S, Esmo Guidelines Working Group (2009) Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 20(150):153. https://doi.org/10.1093/annonc/mdp158 CrossRef

Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, Donati C, Ianniello A, Matteucci F, Amadori D (2014) ¹⁷⁷ Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 41:1845–1851. https://doi.org/10.1007/s00259-014-2735-5 CrossRefPubMed

Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S (2015) Specific efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging 42:1238–1246. https://doi.org/10.1007/s00259-015-3041-6 CrossRefPubMed

Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O, Sarnelli A, Bodei L, Garaboldi L, Bartolomei M, Paganelli G (2013) treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 97:347–354. https://doi.org/10.1159/000348394 CrossRefPubMed

Schwarzer G (2012) Meta: meta‐analysis with R. R package version 2.0‐0. https://CRAN.R-project.org/package=meta. Accessed 23 June 2017

Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G (2017) Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther 10:551–557. https://doi.org/10.2147/OTT.S97584 CrossRefPubMedPubMedCentral

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x CrossRefPubMed

Soydal C, Peker A, Ozkan E, Kucuk ON, Kir MK (2016) The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-¹⁷⁷ DOTATATE. Turk J Med Sci 46:409–413. https://doi.org/10.3906/sag-1412-11 CrossRefPubMed

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of ¹⁷⁷Lu-DOTATATE for midgut neuroendocrine tumors. New Engl J Med 376:125–135. https://doi.org/10.1056/NEJMoa1607427 CrossRefPubMed

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008–2012. https://doi.org/10.1001/jama.283.15.2008 CrossRefPubMed

Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kolby L (2010) [¹⁷⁷Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg 34:1368–1372. https://doi.org/10.1007/s00268-009-0387-6 CrossRefPubMed

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181. https://doi.org/10.1016/s1053-4296(03)00031-6 CrossRefPubMed

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-Dota(0),Tyr(3)-octreotide and (177)Lu-Dota(0), Tyr(3)-octreotate. J Nucl Med 46:83s–91s. https://jnm.snmjournals.org/content/46/1_suppl/83S.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147–156. https://doi.org/10.1053/j.semnuclmed.2006.01.001 CrossRefPubMed

van Binnebeek S, Vanbilloen B, Baete K et al (2016) Comparison of diagnostic accuracy of (111)in-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol 26:900–909. https://doi.org/10.1007/s00330-015-3882-1 CrossRefPubMed

van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ (2010) Salvage therapy with ¹⁷⁷Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 51:383–390. https://doi.org/10.2967/jnumed.109.068957 CrossRefPubMed

van Vliet EI, Krenning EP, Teunissen JJ, Bergsma H, Kam BL, Kwekkeboom DJ (2013) Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [¹⁷⁷Lu-DOTA0, Tyr3]octreotate. J Nucl Med 54:1689–1696. https://doi.org/10.2967/jnumed.112.117408 CrossRefPubMed

Velikyan I, Xu H, Nair M, Hall H (2012) Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol 39:628–639. https://doi.org/10.1016/j.nucmedbio.2011.12.010 CrossRefPubMed

Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K (2015) 68Gallium- and 90Yttrium-/ ¹⁷⁷Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med 29:1–7. https://doi.org/10.1007/s12149-014-0898-6 CrossRefPubMed

Titel: The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
verfasst von: Jie Zhang
Qi Song
Liang Cai
Ying Xie
Yue Chen
Publikationsdatum: 12.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03181-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of VEGFR2-targeted CD-TK-loaded cationic nanobubbles in the treatment of bladder cancer

Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort

Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis

Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma

Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively

High MICB expression as a biomarker for good prognosis of colorectal cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie